SRX Global Inc. has filed a Form 8-K with the SEC regarding a significant acquisition deal. The filing, dated October 6, 2026, outlines the company's agreement to acquire CERo Therapeutics Holdings, Inc., which could have major implications for its operations and financial outlook.
Background on SRX Global Inc.
SRX Global Inc., based in North Palm Beach, Florida, is a company primarily involved in the beverage industry. Previously known as SRx Health Solutions, Inc., it has undergone several name changes, reflecting its evolving business focus. The company is incorporated in Delaware and is publicly traded on the NYSE American under the ticker symbol SRXH.
Details of the Filing
The filing, accessible under accession number 0001493152-26-046085, indicates that SRX Global Inc. entered into a Stock Purchase Agreement with CERo Therapeutics Holdings, Inc. The agreement allows SRX to acquire all outstanding capital stock of CERo Therapeutics, Inc., which is a wholly owned subsidiary of Holdings. This acquisition is referred to as the “Transaction.”
Upon completion of the Transaction, CERo Therapeutics will become a wholly owned subsidiary of SRX Global. The filing also mentions that the maturity date of a previously entered Consolidated Senior Secured Promissory Note will be extended to five business days following the earlier of the Closing Date or the valid termination of the Purchase Agreement.
"The Company will acquire from Holdings all of the outstanding capital stock of CERo Therapeutics, Inc., which acquisition is referred to herein as the ‘Transaction.’"
Financial Considerations
At the Closing, SRX Global will issue shares of its common stock valued at $1,000,000 to Holdings. The share price will be determined based on the lower of the closing price on the trading day before the Purchase Agreement date or the 20-day volume-weighted average price (VWAP) of the stock. Additionally, SRX will forgive all obligations under the Consolidated Note, which has an outstanding balance of approximately $8.25 million.
The company will also assume certain liabilities specified in the Purchase Agreement, amounting to approximately $1.56 million. This will include defending and indemnifying Holdings and its current and former officers and directors against any claims arising from the assumed liabilities.
Impact of the Acquisition
This acquisition is significant for SRX Global as it expands its portfolio and strengthens its position in the market. The deal may affect various stakeholders, including shareholders, employees, and customers. Shareholders may be particularly interested in how this acquisition will impact the company's future earnings and growth potential.
Employees of both SRX Global and CERo Therapeutics may experience changes in their roles and responsibilities as the two companies integrate. Customers may also see new products or services as a result of the merger.
Next Steps
The Purchase Agreement includes a 30-day go-shop period, allowing Holdings to seek alternative acquisition proposals. If a superior proposal is received, Holdings may negotiate and execute a new agreement. This process will provide an opportunity for other potential buyers to express interest in acquiring Holdings.
The filing does not specify what happens next beyond the go-shop period, leaving room for potential developments in the coming weeks.